Literature DB >> 22829597

A unique loop structure in oncostatin M determines binding affinity toward oncostatin M receptor and leukemia inhibitory factor receptor.

Srinivas Chollangi1, Timothy Mather, Karla K Rodgers, John D Ash.   

Abstract

Oncostatin M (OSM) and leukemia inhibitory factor are pleiotropic cytokines that belong to the interleukin-6 (IL-6) family. These cytokines play a crucial role in diverse biological events like inflammation, neuroprotection, hematopoiesis, metabolism, and development. The family is grouped together based on structural similarities and their ability to activate the transmembrane receptor glycoprotein 130 (gp130). The common structure among these cytokines defines the spacing and the orientation of binding sites for cell surface receptors. OSM is unique in this family as it can signal using heterodimers of gp130 with either leukemia inhibitory factor receptor (LIFR) (type I) or oncostatin M receptor (OSMR) (type II). We have identified a unique helical loop on OSM between its B and C helices that is not found on other IL-6 family cytokines. This loop is located near the "FXXK" motif in active site III, which is essential for OSM's binding to both LIFR and OSMR. In this study, we show that the BC loop does not play a role in OSM's unique ability to bind OSMR. Shortening of the loop enhanced OSM's interaction with OSMR and LIFR as shown by kinetic and equilibrium binding analysis, suggesting the loop may hinder receptor interactions. As a consequence of improved binding, these structurally modified OSMs exhibited enhanced biological activity, including suppressed proliferation of A375 melanoma cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22829597      PMCID: PMC3463309          DOI: 10.1074/jbc.M112.387324

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

Review 1.  Interleukin-6 receptor and signals.

Authors:  T Taga; M Hibi; M Murakami; M Saito; H Yawata; M Narazaki; Y Hirata; T Sugita; K Yasukawa; T Hirano
Journal:  Chem Immunol       Date:  1992

2.  Tandem linkage of genes coding for leukemia inhibitory factor (LIF) and oncostatin M (OSM) on human chromosome 22.

Authors:  M Giovannini; M Djabali; D McElligott; L Selleri; G A Evans
Journal:  Cytogenet Cell Genet       Date:  1993

3.  The genes for oncostatin M (OSM) and leukemia inhibitory factor (LIF) are tightly linked on human chromosome 22.

Authors:  T M Rose; M J Lagrou; I Fransson; B Werelius; O Delattre; G Thomas; P J de Jong; G J Todaro; J P Dumanski
Journal:  Genomics       Date:  1993-07       Impact factor: 5.736

4.  Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130.

Authors:  C Lütticken; U M Wegenka; J Yuan; J Buschmann; C Schindler; A Ziemiecki; A G Harpur; A F Wilks; K Yasukawa; T Taga
Journal:  Science       Date:  1994-01-07       Impact factor: 47.728

5.  Close proximity of the genes for leukemia inhibitory factor and oncostatin M.

Authors:  E Jeffery; V Price; D P Gearing
Journal:  Cytokine       Date:  1993-03       Impact factor: 3.861

6.  LIFR beta and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor.

Authors:  S Davis; T H Aldrich; N Stahl; L Pan; T Taga; T Kishimoto; N Y Ip; G D Yancopoulos
Journal:  Science       Date:  1993-06-18       Impact factor: 47.728

7.  Preconditioning-induced protection from oxidative injury is mediated by leukemia inhibitory factor receptor (LIFR) and its ligands in the retina.

Authors:  Srinivas Chollangi; Jiangang Wang; Aaron Martin; John Quinn; John D Ash
Journal:  Neurobiol Dis       Date:  2009-04-01       Impact factor: 5.996

8.  Localization of the human oncostatin M gene (OSM) to chromosome 22q12, distal to the Ewing's sarcoma breakpoint.

Authors:  M Giovannini; L Selleri; G G Hermanson; G A Evans
Journal:  Cytogenet Cell Genet       Date:  1993

9.  Selective regulation of metalloproteinase inhibitor (TIMP-1) by oncostatin M in fibroblasts in culture.

Authors:  C D Richards; M Shoyab; T J Brown; J Gauldie
Journal:  J Immunol       Date:  1993-06-15       Impact factor: 5.422

10.  IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase.

Authors:  M Murakami; M Hibi; N Nakagawa; T Nakagawa; K Yasukawa; K Yamanishi; T Taga; T Kishimoto
Journal:  Science       Date:  1993-06-18       Impact factor: 47.728

View more
  7 in total

1.  The AB loop and D-helix in binding site III of human Oncostatin M (OSM) are required for OSM receptor activation.

Authors:  Juan M Adrian-Segarra; Natalie Schindler; Praveen Gajawada; Holger Lörchner; Thomas Braun; Jochen Pöling
Journal:  J Biol Chem       Date:  2018-03-06       Impact factor: 5.157

2.  Genome-wide association study reveals a QTL and strong candidate genes for umbilical hernia in pigs on SSC14.

Authors:  Eli Grindflek; Marianne H S Hansen; Sigbjørn Lien; Maren van Son
Journal:  BMC Genomics       Date:  2018-05-29       Impact factor: 3.969

Review 3.  Oncostatin M, an Underestimated Player in the Central Nervous System.

Authors:  Evelien Houben; Niels Hellings; Bieke Broux
Journal:  Front Immunol       Date:  2019-05-29       Impact factor: 7.561

4.  Concomitant Activation of OSM and LIF Receptor by a Dual-Specific hlOSM Variant Confers Cardioprotection after Myocardial Infarction in Mice.

Authors:  Holger Lörchner; Juan M Adrian-Segarra; Christian Waechter; Roxanne Wagner; Maria Elisa Góes; Nathalie Brachmann; Krishnamoorthy Sreenivasan; Astrid Wietelmann; Stefan Günther; Nicolas Doll; Thomas Braun; Jochen Pöling
Journal:  Int J Mol Sci       Date:  2021-12-29       Impact factor: 5.923

5.  Proteomic analyses do not reveal subclinical inflammation in fatigued patients with clinically quiescent inflammatory bowel disease.

Authors:  Arno R Bourgonje; Sietse J Wichers; Shixian Hu; Hendrik M van Dullemen; Marijn C Visschedijk; Klaas Nico Faber; Eleonora A M Festen; Gerard Dijkstra; Janneke N Samsom; Rinse K Weersma; Lieke M Spekhorst
Journal:  Sci Rep       Date:  2022-08-26       Impact factor: 4.996

6.  EC330, a small-molecule compound, is a potential novel inhibitor of LIF signaling.

Authors:  Xuetian Yue; Fangnan Wu; Jianming Wang; Kaitlin Kim; Bindu Santhamma; Kalarickal V Dileep; Kam Y J Zhang; Suryavathi Viswanadhapalli; Ratna K Vadlamudi; Gulzar Ahmed; Zhaohui Feng; Klaus Nickisch; Wenwei Hu
Journal:  J Mol Cell Biol       Date:  2020-07-03       Impact factor: 6.216

7.  Prokaryotic soluble overexpression and purification of oncostatin M using a fusion approach and genetically engineered E. coli strains.

Authors:  Minh Tan Nguyen; Musharrat Jahan Prima; Jung-A Song; Julee Kim; Bich Hang Do; Jiwon Yoo; Sangsu Park; Jaepyeong Jang; Sunju Lee; Eunyoung Lee; Michelle de Paula Novais; Hyeon-Beom Seo; Seon-Yeong Lee; Mi-La Cho; Chong Jai Kim; Yeon Jin Jang; Han Choe
Journal:  Sci Rep       Date:  2019-09-23       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.